Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Up 17.4% in December

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 10,440,000 shares, a growth of 17.4% from the December 15th total of 8,890,000 shares. Currently, 16.0% of the shares of the stock are short sold. Based on an average daily volume of 1,660,000 shares, the short-interest ratio is presently 6.3 days.

Institutional Trading of Kura Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of KURA. Suvretta Capital Management LLC grew its holdings in shares of Kura Oncology by 8.2% in the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company's stock valued at $149,535,000 after purchasing an additional 583,155 shares in the last quarter. Armistice Capital LLC boosted its position in Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company's stock valued at $48,386,000 after buying an additional 302,000 shares during the period. Alethea Capital Management LLC grew its stake in shares of Kura Oncology by 108.2% in the third quarter. Alethea Capital Management LLC now owns 553,542 shares of the company's stock worth $10,816,000 after acquiring an additional 287,636 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Kura Oncology during the third quarter worth $3,695,000. Finally, Integral Health Asset Management LLC acquired a new stake in shares of Kura Oncology in the second quarter valued at $2,059,000.

Kura Oncology Trading Up 1.1 %

Kura Oncology stock traded up $0.08 during trading on Friday, hitting $7.26. The company had a trading volume of 1,174,495 shares, compared to its average volume of 1,533,541. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The company's 50 day simple moving average is $10.51 and its 200-day simple moving average is $16.33. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17. The stock has a market cap of $564.54 million, a price-to-earnings ratio of -3.08 and a beta of 0.81.

Analyst Ratings Changes

KURA has been the topic of a number of recent research reports. Lifesci Capital raised Kura Oncology to a "strong-buy" rating in a research note on Tuesday, October 22nd. JMP Securities reissued a "market outperform" rating and set a $32.00 price target on shares of Kura Oncology in a research report on Tuesday, November 19th. HC Wainwright upped their price objective on shares of Kura Oncology from $32.00 to $37.00 and gave the company a "buy" rating in a report on Thursday, November 21st. TD Cowen reaffirmed a "buy" rating on shares of Kura Oncology in a research note on Thursday, November 21st. Finally, UBS Group started coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They issued a "buy" rating and a $27.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Kura Oncology currently has a consensus rating of "Moderate Buy" and a consensus target price of $27.38.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.